Arcturus Therapeutics Holdings, Inc.
http://www.arcturusrx.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arcturus Therapeutics Holdings, Inc.
Arcturus Could Find Its COVID-19 Vaccine Limited To Smaller Markets
The company plans to seek an EUA in Vietnam for ARCT-154, but some analysts have questioned its prospects in major markets like the US.
Finance Watch: AbCellera, 4DMT, Nanobiotix IPOs Bring In $775m Combined
Public Company Edition: Lilly’s COVID-19 antibody partner AbCellera launched one of the biggest IPOs of 2020, bringing in $483m. Also, two more SPACs went public; Sinovac, Biocryst and Kura Oncology arranged large financings; and Viatris plans post-merger layoffs.
Coronavirus Notebook: EU Strikes Deals For Gilead’s Veklury, Janssen’s Vaccine
Russia is planning to register a second COVID-19 vaccine this month, while the UK is ramping up its manufacturing capacity for vaccines and therapeutics.
Finance Watch: CureVac’s IPO Is Ready For Launch
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.